UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2019
Vaxart, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35285 |
|
59-1212264 |
|
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
290 Utah Ave. Suite 200 South San Francisco, California |
|
94080 |
|||
|
(Address of principal executive offices) |
|
(Zip Code) |
|||
Registrant’s telephone number, including area code: (650) 550-3500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading symbol |
|
Name of each exchange on which registered |
|
Common stock, $0.10 par value |
|
VXRT |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 1.02 |
Termination of a Material Definitive Agreement. |
Loan and Security Agreement with Oxford Finance LLC
On November 4, 2019, Vaxart, Inc. paid Oxford Finance LLC $2.4 million, constituting all amounts then owing under our loan and security agreement, dated December 22, 2016, as amended on February 13, 2018, by and among Oxford Finance LLC and us, and certain of our subsidiaries, thereby terminating the loan and security agreement. We also reimbursed Oxford Finance $2,000 of legal fees in connection with such repayment and termination. No prepayment penalties or other amounts were paid to Oxford Finance.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Vaxart, Inc. | |||
| Date: November 7, 2019 | By: | /s/ Wouter W. Latour, M.D. | |
| Name: Wouter W. Latour, M.D. | |||
| Title: President and Chief Executive Officer | |||